NEW YORK – Revolution Medicines can initiate an expanded access treatment protocol for its investigational RAS(ON) inhibitor daraxonrasib for pancreatic cancer, the US Food and Drug Administration ...

NEW YORK – The majority of experts on a US Food and Drug Administration advisory committee found that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation ...

NEW YORK – Amgen recorded double-digit growth for its KRAS inhibitor Lumakras (sotorasib) in the first quarter of 2025 but also announced it is discontinuing development of AMG 193, an MTA-cooperative ...

The firm, having run into roadblocks trying to bring AMT-130 to market in the US, said it is "actively pursuing" regulatory approvals internationally.

The agency's decision was based on data from the VERITAC-2 trial, which showed Veppanu improved progression-free survival by nearly three months over fulvestrant.

NEW YORK – The majority of experts on a US Food and Drug Administration advisory panel on Thursday remained unconvinced that there's sufficient evidence to support giving certain advanced breast ...

NEW YORK – Kestrel Therapeutics said today that it has signed an agreement with AbbVie under which AbbVie will fund the development of its KST-6051 pan-KRAS inhibitor in exchange for the exclusive ...

NEW YORK - The National MPS Society this week said it is awarding a $4 million grant to support a gene therapy program for mucopolysaccharidoses (MPS) IIIB (Sanfilippo syndrome type B) led by ...

NEW YORK – Merck expects its proposed acquisition of Terns Pharmaceuticals to strengthen and diversify its pipeline, which is staring down patent expirations for its top-selling product, the ...